T. Rowe Price Associates’s OPTIMER PHARMACEUTICALS, INC. COM STK OPTR Stock Holding History

T. Rowe Price Associates’s Portfolio OPTR Stock Details OPTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-2,466,300	Closed	-$31.1M	–	2573
2013 Q3	$31.1M	Sell	2,466,300 -2,660,708	-52%	-$35.3M	0.01%	967
2013 Q2	$74.2M	Buy	+5,127,008	New	+$74.7M	0.02%	660

T. Rowe Price Associates's OPTR Position: Q4 2013 in Review

T. Rowe Price Associates sold out of OPTIMER PHARMACEUTICALS, INC. COM STK (OPTR) in Q4 2013, closing a stake of 2,466,300 shares — an estimated $31.1M sold.

T. Rowe Price Associates first reported a position in OPTR in Q2 2013 and held it in 2 quarters. The position peaked at $74.2M in Q2 2013. 0 funds tracked by Wall St. Rank hold OPTR as of Q4 2013.

T. Rowe Price Associates reported no remaining OPTIMER PHARMACEUTICALS, INC. COM STK position as of Q4 2013 after selling out during the quarter.
T. Rowe Price Associates sold 2,466,300 OPTIMER PHARMACEUTICALS, INC. COM STK shares in Q4 2013, an estimated $31.1M.
T. Rowe Price Associates first reported a position in OPTIMER PHARMACEUTICALS, INC. COM STK in Q2 2013 and held it in 2 quarters.
T. Rowe Price Associates's OPTIMER PHARMACEUTICALS, INC. COM STK position peaked at $74.2M in Q2 2013.
0 funds tracked by Wall St. Rank held OPTIMER PHARMACEUTICALS, INC. COM STK as of Q4 2013.

Based on T. Rowe Price Associates's 13F filing for Q4 2013, filed 14 Feb 2014.